One of the most exciting drugs of 2012 was VX-770 or Kalydeco, as it is commercially known developed by Vertex Pharmaceuticals. This drug was developed with strong support from the indomitable Cystic Fibrosis Foundation. In about 4-5% of cystic fibrosis patients, the G551D mutation, in the massive cystic fibrosis transmembrane conductance regulator gene (CFTR), leads… Continue reading Personalized medicine starts with the genetic code